IGF-1 LR3 Research
Performance & EnergyKey peer-reviewed studies on IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor-1). Research is primarily preclinical \u2014 human clinical data is limited. IGF-1 LR3 is banned by WADA and not FDA approved. Each summary is written in plain English. Click any title to read the full article.
Rodino-Klapac LR, Mendell JR, Sahenk Z
A comprehensive review of IGF-1 and its analogs for muscle therapeutic applications, directly relevant to understanding IGF-1 LR3’s research context. The paper examines how structural modifications to native IGF-1 — including those that produced IGF-1 LR3 — affect its biological activity, binding protein interactions, and therapeutic potential. It covers the PI3K/Akt/mTOR signaling cascade that drives muscle protein synthesis and explains why reduced binding to IGF-binding proteins (IGFBPs) — IGF-1 LR3’s key modification — produces more sustained and potent anabolic signaling than native IGF-1.
The Peptide University Research Team
A detailed mechanistic overview of IGF-1 LR3’s action in skeletal muscle. The paper explains how IGF-1 LR3 activates the IGF-1 receptor (IGF-1R), triggering two key downstream cascades — the PI3K/Akt/mTOR pathway (driving protein synthesis and hypertrophy) and the MAPK/ERK pathway (driving cell proliferation and differentiation). It also covers IGF-1 LR3’s nutrient partitioning effects — preferentially directing glucose and amino acids toward muscle tissue rather than fat — and its role in satellite cell activation critical for muscle repair.
Seppälä T — Finnish Center for Integrity in Sports (FINCIS)
A clear-eyed analysis of IGF-1 LR3 from a sports medicine and anti-doping perspective. The paper explains how LR3IGF-1 is physiologically stronger and longer-lasting than native IGF-1, why it is banned in competitive sports, and what the known adverse effects include — particularly hypoglycemia (low blood sugar) from its insulin-like activity. It notes that the risk of adverse effects increases significantly with doses above 60–80 µg/kg/day, and that most adverse effects parallel those of native IGF-1. An important resource for understanding why WADA prohibits IGF-1 LR3.
Genesis Publications Research Group
A 2025 evidence review covering IGF-1 LR3 in the context of performance peptides. The paper confirms IGF-1 LR3’s well-defined molecular mechanism — acting as a powerful anabolic agent through IGF-1R/IRS1/PI3K/Akt cascade activation — while being direct about the evidence gap: no human clinical trials exist, all efficacy data comes from preclinical models, and the compound carries real metabolic and proliferative risks. The review also discusses typical research protocols (20–100 µg/day, 4–6 week cycles with rest periods to prevent receptor desensitization) and notes that IGF-1 LR3 is prohibited by WADA and not FDA approved for human use.
View the full IGF-1 LR3 profile
Mechanism of action, pharmacokinetics, research limitations, and WADA status.
IGF-1 LR3 ProfileWhere to buy IGF-1 LR3
8 research suppliers on our vetted list carry IGF-1 LR3. All are third-party tested with published Certificates of Analysis.